11:02 AM EDT, 05/02/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that an interim analysis of a phase 3 trial showed that Calquence plus chemoimmunotherapy, bendamustine and rituximab showed a "statistically significant and clinically meaningful improvement" in progression-free survival in adults with mantle cell lymphoma, a rare form of non-Hodgkin's lymphoma.

A trend was also seen in favor of the Calquence combination for the secondary endpoint of overall survival, but the results "were not mature" and the trial is proceeding to evaluate overall survival, according to the company.

The safety of Calquence was consistent with its known safety profile, AstraZeneca ( AZN ) said, adding no new safety signals were identified.

Calquence is being assessed alone and in combination to potentially treat several B-cell blood cancers, the company said.

Price: 75.93, Change: -0.48, Percent Change: -0.63